Sarepta Therapeutics Inc. (SRPT)
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SRPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.43B
- P/E (TTM)
- 666.50
- Forward P/E
- 8.87
- EPS (TTM)
- $0.02
- Dividend yield
- None
- 52-week range
- 13.25 – 24.68
- Day range
- 13.25 – 14.47
- Volume / Avg
- 2.24M / 2.70M
- Beta
- —
- Shares outstanding
- 107.24M
52-week range
SRPT stock today
Shares of Sarepta Therapeutics (SRPT) finished lower on Nov 20 at $13.33, a drop of 5.93% or $0.84 per share, versus the S&P 500's 3.70% decline. Shares are 46.0% below their 52-week high of $24.68, set on Jan 26, 2026 and 0.6% above the 52-week low of $13.25, near the bottom of the past year's range. SRPT is down 38.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.6%.
At 666.5x trailing earnings, Sarepta Therapeutics trades above the peer-group median of 7.2x. Its forward P/E of 8.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Sarepta Therapeutics
Company profileSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael E. Severino M.D.
- Headquarters
- Cambridge, MA
- Employees
- 835
- Website
- sarepta.com
Financial highlights
Full financialsIn fiscal 2025, Sarepta Therapeutics generated $2.20 billion in revenue, up 15.6% from fiscal 2024, its 10th consecutive year of revenue growth. Sarepta Therapeutics reported a net loss of $713.4 million, compared with net income of $235.2 million a year earlier. Gross margin was 98.8% and operating margin -31.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M |
| Growth | +15.58% | +52.97% | +33.26% | +32.93% | +29.96% |
| Net income | $-713.41M | $235.24M | $-535.98M | $-703.49M | $-418.78M |
| EPS (diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 |
Analyst forecast
ForecastConsensus (24 analysts)
hold
Avg. price target
$21.77+63.32%
- Strong buy 0
- Buy 7
- Hold 13
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.28 vs $0.17
- Surprise
- -264.71%
SRPT news
All SRPT news- Sarepta (SRPT) Q3 2026 Earnings Call TranscriptNasdaq
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineNasdaqSRPT, AMRX, IBRX
- Sarepta Therapeutics Non-GAAP EPS of $0.13 misses by $0.23, revenue of $381.3M beats by $31.2MSeeking Alpha
- Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate DevelopmentsBusiness Wire
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial ResultsBusiness Wire
Sarepta Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs SRPT |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs SRPT |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs SRPT |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs SRPT |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs SRPT |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs SRPT |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs SRPT |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs SRPT |
Indexes, lists and sector
Sarepta Therapeutics stock FAQ
What is Sarepta Therapeutics's stock price today?
SRPT last traded at $13.33 as of Nov 20, 4:00 PM EST, down 5.93% on the day. Prices are delayed at least 15 minutes.
Does Sarepta Therapeutics pay a dividend?
No. Sarepta Therapeutics does not currently pay a regular cash dividend.
What is SRPT's P/E ratio?
SRPT trades at a trailing P/E ratio of 666.50 and a forward P/E of 8.87, compared with a median of 7.2 for its closest peers.
Who is Sarepta Therapeutics's CEO?
Dr. Michael E. Severino M.D. is the chief executive officer of Sarepta Therapeutics Inc., which has about 835 employees.
Has SRPT ever split its stock?
Yes. The most recent SRPT stock split was a 1-for-6 split on Jul 12, 2012.
What is the SRPT 52-week high?
The 52-week high for SRPT is $24.68 and the 52-week low is $13.25. The stock is currently 46.0% below its high.